HC Wainwright Reiterates Buy Rating for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN:PTN)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock.

Palatin Technologies Trading Up 2.9 %

PTN opened at $1.08 on Thursday. The stock has a market capitalization of $21.11 million, a PE ratio of -0.52 and a beta of 0.99. Palatin Technologies has a 12 month low of $0.68 and a 12 month high of $5.65.

Palatin Technologies (NYSEAMERICAN:PTN) last released its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) EPS for the quarter. On average, analysts predict that Palatin Technologies will post -2.03 earnings per share for the current year.

Institutional Trading of Palatin Technologies

A hedge fund recently bought a new stake in Palatin Technologies stock. XTX Topco Ltd bought a new position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,631 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. XTX Topco Ltd owned about 0.08% of Palatin Technologies at the end of the most recent reporting period. Institutional investors own 11.50% of the company’s stock.

About Palatin Technologies

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.